Home › Therapeutic areas › Ophthalmology › Geographic Atrophy
Geographic Atrophy (5 companies)
Companies with an active program in Geographic Atrophy.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics | OphthalmologyRespiratory Rare | 1 | Phase 3 | $677M | 5 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 1 | Phase 3 | $796M | 6 |
| BLTE | Belite Bio | MetabolicOphthalmology Rare | 1 | NDA Submitted | $6.21B | 6 |
| LCTX | Lineage Cell Therapeutics | MetabolicNeurology+1 Rare | 1 | Phase 2 | $258M | 12 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 1 | Phase 3 | $314M | 12 |
No companies match.